Your browser doesn't support javascript.
loading
miR-21 antagonism reprograms macrophage metabolism and abrogates chronic allograft vasculopathy.
Usuelli, Vera; Ben Nasr, Moufida; D'Addio, Francesca; Liu, Kaifeng; Vergani, Andrea; El Essawy, Basset; Yang, Jun; Assi, Emma; Uehara, Mayuko; Rossi, Chiara; Solini, Anna; Capobianco, Annalisa; Rigamonti, Elena; Potena, Luciano; Venturini, Massimo; Sabatino, Mario; Bottarelli, Lorena; Ammirati, Enrico; Frigerio, Maria; Castillo-Leon, Eduardo; Maestroni, Anna; Azzoni, Cinzia; Loretelli, Cristian; Joe Seelam, Andy; Tai, Albert K; Pastore, Ida; Becchi, Gabriella; Corradi, Domenico; Visner, Gary A; Zuccotti, Gian V; Chau, Nelson B; Abdi, Reza; Pezzolesi, Marcus G; Fiorina, Paolo.
Afiliación
  • Usuelli V; International Center for T1D, Pediatric Clinical Research Center "Romeo ed Enrica Invernizzi", Department of Biomedical and Clinical Science L. Sacco, Universita Degli Studi di Milano, Milan, Italy.
  • Ben Nasr M; International Center for T1D, Pediatric Clinical Research Center "Romeo ed Enrica Invernizzi", Department of Biomedical and Clinical Science L. Sacco, Universita Degli Studi di Milano, Milan, Italy.
  • D'Addio F; Nephrology Division, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Liu K; International Center for T1D, Pediatric Clinical Research Center "Romeo ed Enrica Invernizzi", Department of Biomedical and Clinical Science L. Sacco, Universita Degli Studi di Milano, Milan, Italy.
  • Vergani A; Division of Pulmonary and Respiratory Diseases, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.
  • El Essawy B; Nephrology Division, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Yang J; Department of Medicine, Al-Azhar University, Cairo, Egypt.
  • Assi E; Renal Division, Transplantation Research Center, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Uehara M; Institute of Organ Transplantation, Tongji Hospital and Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Rossi C; International Center for T1D, Pediatric Clinical Research Center "Romeo ed Enrica Invernizzi", Department of Biomedical and Clinical Science L. Sacco, Universita Degli Studi di Milano, Milan, Italy.
  • Solini A; Renal Division, Transplantation Research Center, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Capobianco A; Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
  • Rigamonti E; Department of Surgical, Medical, Molecular and Critical Area Pathology, University of Pisa, Pisa, Italy.
  • Potena L; Division of Immunology, Transplantation and Infectious Disease, San Raffaele Scientific Institute, Milan, Italy.
  • Venturini M; Division of Immunology, Transplantation and Infectious Disease, San Raffaele Scientific Institute, Milan, Italy.
  • Sabatino M; Heart Failure and Heart Transplant Program, S. Orsola-Malpighi Hospital, Alma-Mater University of Bologna, Bologna, Italy.
  • Bottarelli L; Department of Radiology, San Raffaele Scientific Institute, Milan, Italy.
  • Ammirati E; Department of Cardiothoracic, Transplantation and Vascular Surgery, S. Orsola-Malpighi Hospital, Alma Mater-University of Bologna, Bologna, Italy.
  • Frigerio M; Department of Medicine and Surgery, University of Parma, Parma, Italy.
  • Castillo-Leon E; De Gasperis Cardio Center and Transplant Center, Niguarda Hospital, Milan, Italy.
  • Maestroni A; De Gasperis Cardio Center and Transplant Center, Niguarda Hospital, Milan, Italy.
  • Azzoni C; Nephrology Division, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Loretelli C; International Center for T1D, Pediatric Clinical Research Center "Romeo ed Enrica Invernizzi", Department of Biomedical and Clinical Science L. Sacco, Universita Degli Studi di Milano, Milan, Italy.
  • Joe Seelam A; Department of Medicine and Surgery, University of Parma, Parma, Italy.
  • Tai AK; International Center for T1D, Pediatric Clinical Research Center "Romeo ed Enrica Invernizzi", Department of Biomedical and Clinical Science L. Sacco, Universita Degli Studi di Milano, Milan, Italy.
  • Pastore I; International Center for T1D, Pediatric Clinical Research Center "Romeo ed Enrica Invernizzi", Department of Biomedical and Clinical Science L. Sacco, Universita Degli Studi di Milano, Milan, Italy.
  • Becchi G; Tufts University Core Facility (TUCF) Genomics Core, Tufts University School of Medicine, Boston, Massachusetts.
  • Corradi D; Division of Endocrinology, ASST Fatebenefratelli-Sacco, Milan, Italy.
  • Visner GA; Department of Medicine and Surgery, University of Parma, Parma, Italy.
  • Zuccotti GV; Department of Medicine and Surgery, University of Parma, Parma, Italy.
  • Chau NB; Division of Pulmonary and Respiratory Diseases, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Abdi R; International Center for T1D, Pediatric Clinical Research Center "Romeo ed Enrica Invernizzi", Department of Biomedical and Clinical Science L. Sacco, Universita Degli Studi di Milano, Milan, Italy.
  • Pezzolesi MG; Department of Pediatrics, Buzzi Children's Hospital, Milan, Italy.
  • Fiorina P; Regulus Therapeutics Inc, San Diego, California.
Am J Transplant ; 21(10): 3280-3295, 2021 10.
Article en En | MEDLINE | ID: mdl-33764625
ABSTRACT
Despite much progress in improving graft outcome during cardiac transplantation, chronic allograft vasculopathy (CAV) remains an impediment to long-term graft survival. MicroRNAs (miRNAs) emerged as regulators of the immune response. Here, we aimed to examine the miRNA network involved in CAV. miRNA profiling of heart samples obtained from a murine model of CAV and from cardiac-transplanted patients with CAV demonstrated that miR-21 was most significantly expressed and was primarily localized to macrophages. Interestingly, macrophage depletion with clodronate did not significantly prolong allograft survival in mice, while conditional deletion of miR-21 in macrophages or the use of a specific miR-21 antagomir resulted in indefinite cardiac allograft survival and abrogated CAV. The immunophenotype, secretome, ability to phagocytose, migration, and antigen presentation of macrophages were unaffected by miR-21 targeting, while macrophage metabolism was reprogrammed, with a shift toward oxidative phosphorylation in naïve macrophages and with an inhibition of glycolysis in pro-inflammatory macrophages. The aforementioned effects resulted in an increase in M2-like macrophages, which could be reverted by the addition of L-arginine. RNA-seq analysis confirmed alterations in arginase-associated pathways associated with miR-21 antagonism. In conclusion, miR-21 is overexpressed in murine and human CAV, and its targeting delays CAV onset by reprogramming macrophages metabolism.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Asunto principal: Trasplante de Corazón / MicroARNs Límite: Animals / Humans Idioma: En Revista: Am J Transplant Asunto de la revista: TRANSPLANTE Año: 2021 Tipo del documento: Article País de afiliación: Italia

Texto completo: 1 Colección: 01-internacional Asunto principal: Trasplante de Corazón / MicroARNs Límite: Animals / Humans Idioma: En Revista: Am J Transplant Asunto de la revista: TRANSPLANTE Año: 2021 Tipo del documento: Article País de afiliación: Italia